These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


205 related items for PubMed ID: 38243174

  • 1. Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat.
    Friedrich N, Németh K, Tanner M, Rosta J, Dobos I, Oszlács O, Jancsó G, Messlinger K, Dux M.
    J Headache Pain; 2024 Jan 19; 25(1):9. PubMed ID: 38243174
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Endovanilloids are potential activators of the trigeminovascular nocisensor complex.
    Dux M, Deák É, Tassi N, Sántha P, Jancsó G.
    J Headache Pain; 2016 Jan 19; 17():53. PubMed ID: 27189587
    [Abstract] [Full Text] [Related]

  • 4. Chronic adriamycin treatment impairs CGRP-mediated functions of meningeal sensory nerves.
    Deák É, Rosta J, Boros K, Kis G, Sántha P, Messlinger K, Jancsó G, Dux M.
    Neuropeptides; 2018 Jun 19; 69():46-52. PubMed ID: 29661478
    [Abstract] [Full Text] [Related]

  • 5. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats.
    Johnson KW, Morin SM, Wroblewski VJ, Johnson MP.
    Cephalalgia; 2019 Sep 19; 39(10):1241-1248. PubMed ID: 31003588
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
    Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J, Burstein R.
    J Neurosci; 2017 Nov 01; 37(44):10587-10596. PubMed ID: 28972120
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats.
    Ma QP, Hill R, Sirinathsinghji D.
    Eur J Neurosci; 2001 Jun 01; 13(11):2099-104. PubMed ID: 11422450
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine.
    Messlinger K, Fischer MJ, Lennerz JK.
    Keio J Med; 2011 Jun 01; 60(3):82-9. PubMed ID: 21979827
    [Abstract] [Full Text] [Related]

  • 15. The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats.
    Vogler B, Kuhn A, Mackenzie KD, Stratton J, Dux M, Messlinger K.
    Int J Mol Sci; 2023 Aug 30; 24(17):. PubMed ID: 37686275
    [Abstract] [Full Text] [Related]

  • 16. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide.
    Ottosson A, Edvinsson L.
    Cephalalgia; 1997 May 30; 17(3):166-74. PubMed ID: 9170339
    [Abstract] [Full Text] [Related]

  • 17. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
    Kielbasa W, Helton DL.
    Cephalalgia; 2019 Sep 30; 39(10):1284-1297. PubMed ID: 30917684
    [Abstract] [Full Text] [Related]

  • 18. Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats.
    Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G, Tore F.
    Clin Exp Pharmacol Physiol; 2018 Jun 30; 45(6):536-546. PubMed ID: 29344989
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.